Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 9Recurrence 1Neoplasms, Plasma Cell 1Neoplasms 1

Interventions

pembrolizumab 16Bevacizumab 12Carboplatin 10Nivolumab 8Pemetrexed 7Temozolomide 6Standard of Care 6Exercise 6Cetuximab 6durvalumab 5atezolizumab 5Prednisone 5Cyclophosphamide 5abemaciclib 4Paclitaxel 4Doxorubicin 4Dexamethasone 4Cisplatin 4Blood Specimen Collection 4temsirolimus 3enzalutamide 3dostarlimab 3daratumumab 3cabozantinib 3Rituximab 3Oxaliplatin 3Metformin 3Leucovorin 3Lenalidomide 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × isatuximab × 30 days × Clear all
NCT05145400 2026-06-02

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

UNC Lineberger Comprehensive Cancer Center

Phase 2 Recruiting
50 enrolled
Plasma cell

Multiple Myeloma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡